PURPOSE: To characterize tumor vascularization by dynamic-contrast enhanced (DCE) MRI using low and medium molecular weight paramagnetic contrast agents (CA) and inversion recovery (IR) true fast imaging with steady state precession (TrueFISP) in tumor-bearing rats and mice. MATERIALS AND METHODS: T(1) mapping was performed using IR True FISP in phantoms and in vivo at 4.7 T and validated with a segmented IR gradient-echo (IR GE) method. CA concentration in DCE-MRI studies in vivo was calculated from time-series T(1) maps using the CAs GdDOTA and P792 (low and medium molecular weight, respectively). Standard vascular input functions (VIFs) were measured in the jugular veins and were used for modeling of the CA kinetics with a two-compartment model. In rat breast tumors, vascular permeability (transfer constant K(trans)), fractional plasma volume v(p), and fractional leakage space v(e) were quantified and parametric maps were generated. RESULTS: The IR TrueFISP T(1) was slightly underestimated in phantoms and overestimated in vivo (10%) with respect to IR GE. VIFs showed only small interindividual variation. Mean K(trans) values were 0.062 +/- 0.017 min(-1) for GdDOTA and 0.015 +/- 0.005 min(-1) for P792 (N = 12). Mean v(e) and v(p) values were 0.15 +/- 0.04 (0.09 +/- 0.03) and 0.04 +/- 0.01 (0.03 +/- 0.01) for GdDOTA (P792). CONCLUSION: DCE-MRI with IR TrueFISP provided absolute values for K(trans), v(p), and v(e). Direct comparison between GdDOTA and P792 revealed significant differences in the VIF, model-fit-quality, permeability, leakage space, and plasma volume. The larger molecular weight CA P792 appears to be better for measuring tumor vascular parameters.
PURPOSE: To characterize tumor vascularization by dynamic-contrast enhanced (DCE) MRI using low and medium molecular weight paramagnetic contrast agents (CA) and inversion recovery (IR) true fast imaging with steady state precession (TrueFISP) in tumor-bearing rats and mice. MATERIALS AND METHODS: T(1) mapping was performed using IR True FISP in phantoms and in vivo at 4.7 T and validated with a segmented IR gradient-echo (IR GE) method. CA concentration in DCE-MRI studies in vivo was calculated from time-series T(1) maps using the CAs GdDOTA and P792 (low and medium molecular weight, respectively). Standard vascular input functions (VIFs) were measured in the jugular veins and were used for modeling of the CA kinetics with a two-compartment model. In ratbreast tumors, vascular permeability (transfer constant K(trans)), fractional plasma volume v(p), and fractional leakage space v(e) were quantified and parametric maps were generated. RESULTS: The IR TrueFISP T(1) was slightly underestimated in phantoms and overestimated in vivo (10%) with respect to IR GE. VIFs showed only small interindividual variation. Mean K(trans) values were 0.062 +/- 0.017 min(-1) for GdDOTA and 0.015 +/- 0.005 min(-1) for P792 (N = 12). Mean v(e) and v(p) values were 0.15 +/- 0.04 (0.09 +/- 0.03) and 0.04 +/- 0.01 (0.03 +/- 0.01) for GdDOTA (P792). CONCLUSION:DCE-MRI with IR TrueFISP provided absolute values for K(trans), v(p), and v(e). Direct comparison between GdDOTA and P792 revealed significant differences in the VIF, model-fit-quality, permeability, leakage space, and plasma volume. The larger molecular weight CA P792 appears to be better for measuring tumor vascular parameters.
Authors: R Brian Doctor; Natalie J Serkova; Kendra M Hasebroock; Iram Zafar; Charles L Edelstein Journal: Nephrol Dial Transplant Date: 2010-04-13 Impact factor: 5.992
Authors: Jan Sedlacik; Adrianne Myers; Ralf B Loeffler; Regan F Williams; Andrew M Davidoff; Claudia M Hillenbrand Journal: J Magn Reson Imaging Date: 2012-09-21 Impact factor: 4.813
Authors: Sanaz A Jansen; Tatjana Paunesku; Xiaobing Fan; Gayle E Woloschak; Stefan Vogt; Suzanne D Conzen; Thomas Krausz; Gillian M Newstead; Gregory S Karczmar Journal: Radiology Date: 2009-11 Impact factor: 11.105
Authors: Tista Roy Chaudhuri; Robert D Arnold; Jun Yang; Steven G Turowski; Yang Qu; Joseph A Spernyak; Richard Mazurchuk; Donald E Mager; Robert M Straubinger Journal: Pharm Res Date: 2012-07-14 Impact factor: 4.200
Authors: Tal Teitz; Jennifer J Stanke; Sara Federico; Cori L Bradley; Rachel Brennan; Jiakun Zhang; Melissa D Johnson; Jan Sedlacik; Madoka Inoue; Ziwei M Zhang; Sharon Frase; Jerold E Rehg; Claudia M Hillenbrand; David Finkelstein; Christopher Calabrese; Michael A Dyer; Jill M Lahti Journal: PLoS One Date: 2011-04-29 Impact factor: 3.240
Authors: Sander M Bison; Joost C Haeck; K Bol; S J Koelewijn; H C Groen; M Melis; J F Veenland; M R Bernsen; M de Jong Journal: EJNMMI Res Date: 2015-11-09 Impact factor: 3.138
Authors: Juan E Ortuño; María J Ledesma-Carbayo; Rui V Simões; Ana P Candiota; Carles Arús; Andrés Santos Journal: BMC Bioinformatics Date: 2013-11-04 Impact factor: 3.169
Authors: J C Haeck; K Bol; C M A de Ridder; L Brunel; J A Fehrentz; J Martinez; W M van Weerden; M R Bernsen; M de Jong; J F Veenland Journal: EJNMMI Res Date: 2016-01-14 Impact factor: 3.138